|
1.
|
Levy D, Kenchaiah S, Larson MG, et al:
Long-term trends in the incidence of and survival with heart
failure. N Engl J Med. 347:1397–1402. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Roger VL, Weston SA, Redfield MM, et al:
Trends in heart failure incidence and survival in a community-based
population. JAMA. 292:344–350. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Agarwal AK and Katz SD: Future directions
in management of anemia in heart failure. Heart Fail Clin.
6:385–395. 2010.PubMed/NCBI
|
|
4.
|
Tang WH, Tong W, Jain A, et al: Evaluation
and long-term prognosis of new-onset, transient, and persistent
anemia in ambulatory patients with chronic heart failure. J Am Coll
Cardiol. 51:569–576. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Anand IS, Kuskowski MA, Rector TS, et al:
Anemia and change in hemoglobin over time related to mortality and
morbidity in patients with chronic heart failure: results from
Val-HeFT. Circulation. 112:1121–1127. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
O’Meara E, Clayton T, McEntegart MB, et al
CHARM Committees and Investigators: Clinical correlates and
consequences of anemia in a broad spectrum of patients with heart
failure: results of the Candesartan in Heart Failure: Assessment of
Reduction in Mortality and Morbidity (CHARM) Program. Circulation.
113:986–994. 2006.
|
|
7.
|
Young JB, Abraham WT, Albert NM, et al
OPTIMIZE-HF Investigators and Coordinators: Relation of low
hemoglobin and anemia to morbidity and mortality in patients
hospitalized with heart failure (insight from the OPTIMIZE-HF
registry). Am J Cardiol. 101:223–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Bansal N, Tighiouart H, Weiner D, et al:
Anemia as a risk factor for kidney function decline in individuals
with heart failure. Am J Cardiol. 99:1137–1142. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Felker GM, Adams KF Jr, Gattis WA and
O’Connor CM: Anemia as a risk factor and therapeutic target in
heart failure. J Am Coll Cardiol. 44:959–966. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Caramelo C, Justo S and Gil P: Anemia in
heart failure: pathophysiology, pathogenesis, treatment, and
incognitae. Rev Esp Cardiol. 60:848–860. 2007.(In Spanish).
|
|
11.
|
Terrovitis JV, Anastasiou-Nana M, Kaldara
E, Drakos SG, Nanas SN and Nanas JN: Anemia in heart failure:
pathophysiologic insights and treatment options. Future Cardiol.
5:71–81. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Belonje AM, de Boer RA and Voors AA:
Recombinant human Epo treatment: beneficial in chronic kidney
disease, chronic heart failure, or both? Editorial to: “Correction
of anemia with erythropoietin in chronic kidney disease (stage 3 or
4): effects on cardiac performance by Pappas et al”. Cardiovasc
Drugs Ther. 22:1–2. 2008.
|
|
13.
|
Büyüklü M: Heart failure: erythropoietin
in treatment of anemia. Anadolu Kardiyol Derg. 7:342–343. 2007.(In
Turkish).
|
|
14.
|
Cohen RS, Karlin P, Yushak M, Mancini D
and Maurer MS: The effect of erythropoietin on exercise capacity,
left ventricular remodeling, pressure-volume relationships, and
quality of life in older patients with anemia and heart failure
with preserved ejection fraction. Congest Heart Fail. 16:96–103.
2010.
|
|
15.
|
Kotecha D, Ngo K, Walters JA, Manzano L,
Palazzuoli A and Flather MD: Erythropoietin as a treatment of
anemia in heart failure: systematic review of randomized trials. Am
Heart J. 161:822–831. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Balion C, Santaguida PL, Hill S, et al:
Testing for BNP and NT-proBNP in the diagnosis and prognosis of
heart failure. Evid Rep Technol Assess (Full Rep). 142:1–147.
2006.PubMed/NCBI
|
|
17.
|
Tsutamoto T, Sakai H, Nishiyama K, et al:
Direct comparison of transcardiac increase in brain natriuretic
peptide (BNP) and N-terminal proBNP and prognosis in patients with
chronic heart failure. Circ J. 71:1873–1878. 2007. View Article : Google Scholar
|
|
18.
|
Yu CM, Fung JW, Zhang Q, et al:
Improvement of serum NT-ProBNP predicts improvement in cardiac
function and favorable prognosis after cardiac resynchronization
therapy for heart failure. J Card Fail. 11:S42–46. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Lupón J, Urrutia A, González B, et al:
Prognostic significance of hemoglobin levels in patients with heart
failure. Rev Esp Cardiol. 58:48–53. 2005.(In Spanish).
|
|
20.
|
Varadarajan P, Gandhi S, Sharma S,
Umakanthan B and Pai RG: Prognostic significance of hemoglobin
level in patients with congestive heart failure and normal ejection
fraction. Clin Cardiol. 29:444–449. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Akram K and Pearlman BL: Congestive heart
failure-related anemia and a role for erythropoietin. Int J
Cardiol. 117:296–305. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Ruifrok WP, Qian C, Silljé HH, et al:
Heart failure-associated anemia: bone marrow dysfunction and
response to erythropoietin. J Mol Med (Berl). 89:377–387. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Timmer SA, De Boer K, Knaapen P, Götte MJ
and Van Rossum AC: The potential role of erythropoietin in chronic
heart failure: from the correction of anemia to improved perfusion
and reduced apoptosis? J Card Fail. 15:353–361. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Ogino A, Takemura G, Kawasaki M, et al:
Erythropoietin receptor signaling mitigates renal
dysfunction-associated heart failure by mechanisms unrelated to
relief of anemia. J Am Coll Cardiol. 56:1949–1958. 2010. View Article : Google Scholar
|
|
25.
|
Palazzuoli A, Silverberg D, Iovine F, et
al: Erythropoietin improves anemia exercise tolerance and renal
function and reduces B-type natriuretic peptide and hospitalization
in patients with heart failure and anemia. Am Heart J. 152:1096.
e9–15. 2006.PubMed/NCBI
|
|
26.
|
Tang WH and Yeo PS: Epidemiology of anemia
in heart failure. Heart Fail Clin. 6:271–278. 2010. View Article : Google Scholar
|
